NASDAQ:AMGN - Nasdaq - US0311621009 - Common Stock - Currency: USD
Overall AMGN gets a fundamental rating of 5 out of 10. We evaluated AMGN against 568 industry peers in the Biotechnology industry. While AMGN has a great profitability rating, there are some minor concerns on its financial health. AMGN has a valuation in line with the averages, but it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 4.45% | ||
ROE | 69.59% | ||
ROIC | 9.2% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 21.71% | ||
PM (TTM) | 12.24% | ||
GM | 61.53% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 9.62 | ||
Debt/FCF | 5.78 | ||
Altman-Z | 1.32 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.26 | ||
Quick Ratio | 0.95 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 13.81 | ||
Fwd PE | 13 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 14.16 | ||
EV/EBITDA | 15.35 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 3.43% |
273.68
-3.61 (-1.3%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 3.43% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 13.81 | ||
Fwd PE | 13 | ||
P/S | 4.4 | ||
P/FCF | 14.16 | ||
P/OCF | 12.81 | ||
P/B | 25.04 | ||
P/tB | N/A | ||
EV/EBITDA | 15.35 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 4.45% | ||
ROE | 69.59% | ||
ROCE | 10.56% | ||
ROIC | 9.2% | ||
ROICexc | 11.14% | ||
ROICexgc | 60.62% | ||
OM | 21.71% | ||
PM (TTM) | 12.24% | ||
GM | 61.53% | ||
FCFM | 31.1% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 9.62 | ||
Debt/FCF | 5.78 | ||
Debt/EBITDA | 4.4 | ||
Cap/Depr | 19.6% | ||
Cap/Sales | 3.28% | ||
Interest Coverage | 2.2 | ||
Cash Conversion | 89.42% | ||
Profit Quality | 254.13% | ||
Current Ratio | 1.26 | ||
Quick Ratio | 0.95 | ||
Altman-Z | 1.32 |